Janssen receives positive CHMP opinion for SYMTUZA(TM)
Janssen-Cilag announced that the Committee for Medicinal Products for Human Use of the EMA has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide, a once-daily darunavir-based single tablet regimen. July 21, 2017